Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Roberto Castelli

Showing results (11-20 of 64) with videos related to

Pageof 7
Sort By:
Clinical Lymphoma, Myeloma & Leukemia|November 17, 2012
Immunomodulatory drugs: new options for the treatment of myelodysplastic syndromesRoberto Castelli, Ramona Cassin, Antonino Cannavò, et al.
Cardiovascular & Hematological Disorders Drug Targets|April 16, 2020
HIV-Related Lymphoproliferative Diseases in the Era of Combination Antiretroviral TherapyRoberto Castelli, Riccardo Schiavon, Carlo Preti, et al.
Current Vascular Pharmacology|June 3, 2009
Thromboembolic complications in malignant haematological disordersRoberto Castelli, Barbara Ferrari, Agostino Cortelezzi, et al.
Anti-Cancer Drugs|February 3, 2021
Bendamustine in association with rituximab for first-line treatment of diffuse large B-cell lymphoma in frail patients ineligible for R-CHOP/R-CHOP-like treatmentsRoberto Castelli, Antonio Gidaro, Giorgio L Deliliers, et al.
The American Journal of the Medical Sciences|November 17, 2004
Intrathoracic masses due to extramedullary hematopoiesisRoberto Castelli, Giovanna Graziadei, Mehran Karimi, et al.
Annals of Hematology|March 4, 2017
Biosimilar epoetin alfa increases haemoglobin levels and brings cognitive and socio-relational benefits to elderly transfusion-dependent multiple myeloma patients: results from a pilot studyRoberto Castelli, Simona Sciara, Giorgio Lambertenghi Deliliers, et al.
Medical Oncology (Northwood, London, England)|April 21, 2018
Management of anemia in low-risk myelodysplastic syndromes treated with erythropoiesis-stimulating agents newer and older agentsRoberto Castelli, Riccardo Schiavon, Valentina Rossi, et al.
Expert Review of Hematology|October 27, 2017
Personalized treatment strategies for elderly patients with myelodysplastic syndromesRoberto Castelli, Luigi Bergamaschini, Riccardo Schiavon, et al.
Immunology and Allergy Clinics of North America|November 7, 2006
Acquired deficiency of the inhibitor of the first complement component: presentation, diagnosis, course, and conventional managementLorenza Chiara Zingale, Roberto Castelli, Andrea Zanichelli, et al.
Expert Review of Anticancer Therapy|December 17, 2013
Choosing treatment options for patients with relapsed/refractory multiple myelomaRoberto Castelli, Nicola Orofino, Agnese Losurdo, et al.
Pageof 7

Showing results (11-20 of 64) with videos related to

Sort By:
Pageof 7
Clinical Lymphoma, Myeloma & Leukemia|November 17, 2012
Immunomodulatory drugs: new options for the treatment of myelodysplastic syndromesRoberto Castelli, Ramona Cassin, Antonino Cannavò, et al.
Cardiovascular & Hematological Disorders Drug Targets|April 16, 2020
HIV-Related Lymphoproliferative Diseases in the Era of Combination Antiretroviral TherapyRoberto Castelli, Riccardo Schiavon, Carlo Preti, et al.
Current Vascular Pharmacology|June 3, 2009
Thromboembolic complications in malignant haematological disordersRoberto Castelli, Barbara Ferrari, Agostino Cortelezzi, et al.
Anti-Cancer Drugs|February 3, 2021
Bendamustine in association with rituximab for first-line treatment of diffuse large B-cell lymphoma in frail patients ineligible for R-CHOP/R-CHOP-like treatmentsRoberto Castelli, Antonio Gidaro, Giorgio L Deliliers, et al.
The American Journal of the Medical Sciences|November 17, 2004
Intrathoracic masses due to extramedullary hematopoiesisRoberto Castelli, Giovanna Graziadei, Mehran Karimi, et al.
Annals of Hematology|March 4, 2017
Biosimilar epoetin alfa increases haemoglobin levels and brings cognitive and socio-relational benefits to elderly transfusion-dependent multiple myeloma patients: results from a pilot studyRoberto Castelli, Simona Sciara, Giorgio Lambertenghi Deliliers, et al.
Medical Oncology (Northwood, London, England)|April 21, 2018
Management of anemia in low-risk myelodysplastic syndromes treated with erythropoiesis-stimulating agents newer and older agentsRoberto Castelli, Riccardo Schiavon, Valentina Rossi, et al.
Expert Review of Hematology|October 27, 2017
Personalized treatment strategies for elderly patients with myelodysplastic syndromesRoberto Castelli, Luigi Bergamaschini, Riccardo Schiavon, et al.
Immunology and Allergy Clinics of North America|November 7, 2006
Acquired deficiency of the inhibitor of the first complement component: presentation, diagnosis, course, and conventional managementLorenza Chiara Zingale, Roberto Castelli, Andrea Zanichelli, et al.
Expert Review of Anticancer Therapy|December 17, 2013
Choosing treatment options for patients with relapsed/refractory multiple myelomaRoberto Castelli, Nicola Orofino, Agnese Losurdo, et al.
Pageof 7